Literature DB >> 23798340

Pleomorphic adenoma of the major salivary glands: diagnostic utility of FNAB and MRI.

Chase M Heaton1, J Levi Chazen, Annemieke van Zante, Christine M Glastonbury, Eric J Kezirian, David W Eisele.   

Abstract

OBJECTIVES/HYPOTHESIS: Pleomorphic adenoma (PA) is the most common, benign tumor of the major salivary glands. Surgical resection is the treatment of choice. Initial preoperative workup of major salivary gland neoplasms often includes fine needle aspiration biopsy (FNAB) and magnetic resonance imaging (MRI) of the head and neck. Our objective was to assess the positive predictive value of FNAB and MRI in the evaluation of PA arising from within the major salivary glands. STUDY
DESIGN: Retrospective chart review.
METHODS: All patients with a FNAB diagnosis of PA of the major salivary glands and who underwent surgical excision at our institution from 2001 to 2011 were identified. FNAB slides from these cases were reviewed by a cytopathologist for findings suggestive of PA: fibrillary stroma, mesenchymal elements, plasmacytoid myoepithelial cells, epithelial cells forming ducts or tubules, and the absence of nuclear atypia. For those patients with a preoperative MRI, the MRI studies were reviewed by a neuroradiologist for findings suggestive of PA, including homogenous T2 hyperintensity, well-circumscribed borders, and solid contrast enhancement. Positive predictive value (PPV) of these specific FNAB and MRI findings were calculated using chi-squared testing.
RESULTS: One hundred forty-six patients met inclusion criteria, and 68 had preoperative MRI. PPV of a FNAB diagnosis of PA was 97.8%. Characteristic features of PA on FNAB (fibrillary stroma, mesenchymal elements, plasmacytoid myoepithelial cells, epithelial cells forming ducts or tubules, and the absence of nuclear atypia) and MRI (homogenous T2 hyperintensity, well-circumscribed borders, and solid contrast enhancement) all demonstrated PPVs of 95% or greater in patients with FNA diagnosis of PA.
CONCLUSIONS: PPV of a FNAB diagnosis of PA in the major salivary glands is high. Among patients with a FNAB diagnosis of PA, specific MRI characteristics also have a high PPV. The diagnostic accuracy of these studies in combination allows for the confident preoperative diagnosis of PA.
Copyright © 2013 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Pleomorphic adenoma; cytopathology; radiology

Mesh:

Year:  2013        PMID: 23798340     DOI: 10.1002/lary.24247

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  5 in total

1.  Preoperative evaluation and treatment consideration of parotid gland tumors.

Authors:  Katri Aro; Jarkko Korpi; Jussi Tarkkanen; Antti Mäkitie; Timo Atula
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-07-20

2.  Soft Palate Pleomorphic Adenoma of a Minor Salivary Gland: An Unusual Presentation.

Authors:  C T Forde; R Millard; S Ali
Journal:  Case Rep Otolaryngol       Date:  2018-03-31

3.  Ultra-small superparamagnetic iron oxide (USPIO) magnetic resonance imaging in benign mixed tumor of the parotid gland.

Authors:  Jason M Johnson; Abdallah S R Mohamed; Yao Ding; Jihong Wang; Stephen Y Lai; Clifton D Fuller; Rutvij Shah; Randall T Butler; Randal S Weber
Journal:  Clin Case Rep       Date:  2020-12-09

4.  MRI findings of epithelial-myoepithelial carcinoma of the parotid gland with radiologic-pathologic correlation.

Authors:  Taketo Suto; Hiroki Kato; Masaya Kawaguchi; Kazuhiro Kobayashi; Tatsuhiko Miyazaki; Tomohiro Ando; Yoshifumi Noda; Fuminori Hyodo; Masayuki Matsuo; Hiromasa Ishihara; Takenori Ogawa
Journal:  Jpn J Radiol       Date:  2022-01-04       Impact factor: 2.701

5.  Preoperative Diagnostic Strategy for Parotid Gland Tumors Using Diffusion-Weighted MRI and Technetium-99m Pertechnetate Scintigraphy: A Prospective Study.

Authors:  Masahiro Kikuchi; Sho Koyasu; Shogo Shinohara; Yukihiro Imai; Megumu Hino; Yasushi Naito
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.